In November 2018, the UK government rescheduled cannabis-based products for medicinal use (CBPMs). For many patients suffering from chronic pain, refractory epilepsy, or multiple sclerosis, this felt like the moment the door was finally opened. Nine years of working in NHS administration taught me that there is a massive difference between a policy change and a change in clinical practice.
While the law changed, the actual availability of medical cannabis on the NHS remained almost non-existent for the vast majority of patients. This post strips away the political messaging to explain why the NHS is still so cautious and how the private sector has filled the void.
The 2018 Legislative Shift: A Regulatory Illusion
Before 2018, cannabis was a Schedule 1 drug, meaning it was viewed as having no therapeutic value. When the Home Office rescheduled it to Schedule 2, it allowed specialist doctors—not GPs—to prescribe it under strict conditions. This was not a "legalization" for everyone; it was a narrow pathway for very specific, treatment-resistant conditions.
The problem is that legislation doesn’t force a clinician to prescribe. Clinical practice is driven by the National Institute for Health and Care Excellence (NICE) guidelines. NICE looks at high-quality, large-scale clinical trials. Because medical cannabis is a complex, multi-component botanical product, it does not fit easily into the standard "one pill, one disease" testing model used for conventional pharmaceuticals.
Cannabinoids are active chemical compounds found in the cannabis plant, while terpenes are the aromatic oils that give the plant its distinct scent and may influence its therapeutic effects. Because the medical community is still gathering data on how these interact, NHS consultants, who carry the weight of individual accountability, are inherently hesitant to prescribe.
Why the NHS Remains Cautious
If you have worked in the NHS, you know that "caution" is often a synonym for "lack of financial and clinical safety." NHS trusts operate under immense financial pressure, https://highstylife.com/what-is-the-role-of-online-patient-onboarding-in-private-cannabis-clinics/ and they prioritize treatments that have a clear, cost-effective, evidence-based mandate.
The "Specialist Only" Bottleneck
NICE guidelines currently only support medical cannabis for a tiny subset of patients, such as those with specific types of epilepsy, multiple sclerosis-related spasticity, or chemotherapy-induced nausea. Even then, the guidelines require that every other licensed medication has been tried and failed first.
This creates an administrative bottleneck. A consultant must prove that they have exhausted every conventional, NHS-approved path before even considering a CBPM. Most consultants are simply not comfortable with this burden, especially when the supporting data is still evolving.
The Rise of Private Clinics
Because the NHS essentially stopped at the threshold of these guidelines, a private market exploded to meet patient demand. These private clinics operate differently, though they are still governed by the Care Quality Commission (CQC) and the General Medical Council (GMC).
Private clinics are not a "miracle cure" provider. They are independent medical practices that apply the same logic of specialist prescribing but with a broader interpretation of what constitutes "treatment-resistant." If you have documented chronic pain or anxiety that has not responded to traditional therapies, a private specialist may be willing to assess you.
The Access Gap
The divide here is clear: access to medical cannabis in the UK is currently determined by your ability to pay. Private prescriptions carry significant costs for the consultation and the medication itself. This creates a two-tier system where those with the means can access treatment, while those reliant on the NHS remain stuck in the referral loop.
The Digital-First Patient Journey
The rapid adoption of telehealth has been the primary engine for private cannabis clinics. By utilizing video consultations, these clinics can reach patients across the UK regardless of geography. This is a massive shift from traditional NHS care, which is often tied to your local Integrated Care Board (ICB) and local hospital catchment areas.
Digital-first patient journeys involve three main https://smoothdecorator.com/is-telehealth-the-main-reason-uk-medical-cannabis-became-more-common/ stages:
The Digital Intake: Patients upload their medical history, including Summary Care Records, through secure patient portals. Telehealth Screening: An initial video consultation assesses eligibility, focusing on "treatment-resistant" history. Electronic Prescription Service (EPS): If approved, the prescription is sent digitally to a specialist pharmacy, which then ships the medication directly to the patient.This digital workflow is efficient, but it also carries risks. It is the responsibility of the patient to ensure they have their medical records ready. Clinics cannot advocate for you if you do not provide the necessary documentation to prove that previous treatments have failed.
Your Pre-Appointment Checklist
Whether you are trying to navigate the NHS or considering a private consultation, you must be prepared. Clinical administrators hate missing records, and your doctor cannot approve a script if they are missing the "paper trail."
Before you book an appointment, make sure you have the following in your digital folder:
- The Summary Care Record (SCR): Ask your GP surgery for a printout or a digital export of your full medical history. List of Tried Treatments: Create a table listing every medication you have tried for your condition, the dosage, the duration, and exactly why it failed (e.g., side effects or lack of efficacy). Specialist Referral Letters: If you have seen a specialist (like a neurologist or rheumatologist) in the last five years, include their letters. Proof of Diagnosis: Ensure your diagnosis is clearly documented and not just a "suspected" condition. Current Medication List: A complete list of your current prescriptions to check for potential contraindications with cannabinoids.
Comparison Table: NHS vs. Private Access
Feature NHS Access Private Access Cost Free at point of use (NHS prescription charge) Out-of-pocket (Consultation fees + medication costs) Wait Times High (Months for specialist referral) Low (Usually days or weeks) Access Threshold Extremely narrow (NICE guidelines) Broader (Clinical discretion based on treatment-resistant history) Delivery Pharmacy collection Direct-to-patient via specialist courier Consultation Type In-person (mostly) Telehealth/Video consultationsFinal Thoughts: Who Is Responsible?
The frustration many patients feel is valid, but it is important to point the finger correctly. It is not the fault of the individual GP; they simply do not have the legal remit to prescribe CBPMs. It is not necessarily the fault of the individual consultant; they are working within a framework of NHS caution that prioritizes long-term, standardized clinical outcomes.
If you are looking for change, it will come from the research sector. Until larger, more robust clinical trials are published—giving NHS consultants the comfort of evidence—access will remain largely locked behind the doors of private practice and digital-first clinics.
If you decide to pursue a consultation, do your homework. Ensure the clinic is CQC-registered, keep your medical records organized, and always be wary of any provider promising a "miracle cure." Reliable healthcare is built on evidence, transparency, and a clear understanding of the patient's history—not marketing fluff.